{"id":"clostridium-butyricum-cbm588-strain","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2108709","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of Clostridium butyricum CBM588 Strain is not fully understood, but it is thought to involve the production of butyrate, a short-chain fatty acid that has anti-inflammatory properties. This may lead to improved gut health and immune function, which could have therapeutic benefits in various conditions.","oneSentence":"Clostridium butyricum CBM588 Strain is a probiotic bacterium that may modulate the gut microbiome to exert therapeutic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:31:20.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Irritable bowel syndrome (IBS)"}]},"trialDetails":[{"nctId":"NCT07474064","phase":"PHASE2","title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","status":"NOT_YET_RECRUITING","sponsor":"chenxu","startDate":"2026-03-26","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":146},{"nctId":"NCT05122546","phase":"PHASE1","title":"CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-01","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma","enrollment":31},{"nctId":"NCT07422103","phase":"NA","title":"PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)","status":"NOT_YET_RECRUITING","sponsor":"Casa di Cura Dott. Pederzoli","startDate":"2026-03-15","conditions":"Pancreatic Cancer, Pancreatic Diseases, Gastrointestinal Symptoms","enrollment":158},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT07037004","phase":"PHASE2","title":"Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-04","conditions":"Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8","enrollment":62},{"nctId":"NCT03922035","phase":"PHASE1","title":"CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-04-18","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":36},{"nctId":"NCT03829111","phase":"PHASE1","title":"CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2019-05-14","conditions":"Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT06399419","phase":"PHASE1","title":"CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer","status":"RECRUITING","sponsor":"Osel, Inc.","startDate":"2024-06-19","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma","enrollment":28},{"nctId":"NCT01077245","phase":"PHASE2","title":"Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections","status":"WITHDRAWN","sponsor":"Osel, Inc.","startDate":"2010-02","conditions":"Clostridium Difficile Infection","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["C. butyricum CBM588 Strain","C. butyricum MIYAIRI Strain","C. butyricum Strain MIYAIRI 588","CBM588","Clostridium butyricum MIYAIRI 588"],"phase":"phase_2","status":"active","brandName":"Clostridium butyricum CBM588 Strain","genericName":"Clostridium butyricum CBM588 Strain","companyName":"City of Hope Medical Center","companyId":"city-of-hope-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clostridium butyricum CBM588 Strain is a probiotic bacterium that may modulate the gut microbiome to exert therapeutic effects. Used for Irritable bowel syndrome (IBS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}